Hemato

Scope & Guideline

Fostering Open Dialogue in Hematological Studies

Introduction

Immerse yourself in the scholarly insights of Hemato with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherMDPI
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationHEMATO-BASEL / Hemato
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND

Aims and Scopes

The journal 'Hemato' primarily focuses on advancing knowledge in the field of hematology through innovative research, clinical studies, and comprehensive reviews. It emphasizes the diagnosis, treatment, and management of hematologic diseases, with a particular attention to novel therapies and patient outcomes.
  1. Hematologic Malignancies:
    A core area of focus is on hematologic malignancies, including various forms of leukemia, lymphoma, and myeloma. The journal publishes research on their molecular mechanisms, treatment strategies, and clinical outcomes.
  2. Transfusion Medicine:
    The journal covers advancements in transfusion medicine, exploring the implications of blood component therapies and their interactions with different treatment modalities, particularly in patients with hematologic disorders.
  3. Innovative Therapies and Technologies:
    There is a strong emphasis on innovative therapies, including immunotherapies, CAR-T cell therapies, and targeted therapies. The journal showcases studies that evaluate the efficacy and safety of these novel treatment approaches.
  4. Clinical and Epidemiological Research:
    The journal publishes clinical and epidemiological studies that provide insights into the prevalence, risk factors, and outcomes of hematologic diseases, contributing to evidence-based practice.
  5. Patient-Centered Care:
    Research on the psychosocial aspects of hematologic diseases, including patient-reported outcomes and quality of life, is also a significant focus, reflecting a commitment to patient-centered care.
The journal 'Hemato' has witnessed a rise in certain themes and areas of research, reflecting the dynamic nature of hematology. These trending and emerging scopes highlight the journal's responsiveness to current challenges and advancements in the field.
  1. Precision Medicine and Genomics:
    There is a growing emphasis on precision medicine and the integration of genomic data into treatment strategies for hematologic diseases, which is crucial for tailoring therapies to individual patient profiles.
  2. Artificial Intelligence and Big Data:
    Emerging research on the application of artificial intelligence and big data analytics in hematology is trending, with studies focusing on predictive modeling and improving diagnostic accuracy.
  3. Immunotherapy Developments:
    The journal has seen an increase in publications related to immunotherapy, particularly CAR-T cell therapy and checkpoint inhibitors, as these modalities continue to revolutionize treatment paradigms.
  4. Management of Comorbidities in Hematologic Patients:
    Research addressing the management of comorbidities, such as cardiovascular issues in patients with hematologic malignancies, is gaining traction, reflecting a holistic approach to patient care.
  5. Global Health Initiatives in Hematology:
    There is an emerging focus on global health initiatives and resource-limited settings, particularly studies aimed at improving care for populations with high burdens of hematologic diseases.

Declining or Waning

As the field of hematology evolves, certain themes and areas of focus within the journal 'Hemato' appear to be declining. This may reflect shifts in research priorities or advancements in treatment that render some topics less relevant.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in publications focused on traditional chemotherapy approaches for hematologic malignancies, as newer targeted therapies and immunotherapies gain prominence.
  2. Historical Epidemiological Studies:
    Studies that primarily focus on historical epidemiological data without integrating new findings or technologies are less frequently published, indicating a shift towards more current and actionable research.
  3. Basic Science Research Without Clinical Application:
    Basic science studies that do not demonstrate a clear clinical application or relevance to patient care are becoming less common, as the journal increasingly prioritizes translational research.

Similar Journals

BONE MARROW TRANSPLANTATION

Elevating Standards in Hematology and Transplantation.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

EUROPEAN JOURNAL OF HAEMATOLOGY

Innovative Insights into Blood Health and Disease
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

BRITISH JOURNAL OF HAEMATOLOGY

Pioneering Insights in Blood Disorders and Treatments
Publisher: WILEYISSN: 0007-1048Frequency: 23 issues/year

British Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.

Hematology

Elevating Hematology: A Platform for Cutting-Edge Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

Indian Journal of Hematology and Blood Transfusion

Exploring Innovations in Blood Disorders and Transfusion Science
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

Blood Cancer Discovery

Catalyzing Change in Cancer Research Landscapes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Enhancing global health with impactful transfusion studies.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

BLOOD

Pioneering Research at the Heart of Hematology.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

LEUKEMIA & LYMPHOMA

Bridging research and clinical practice in blood cancers.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

Journal of Hematology

Connecting Scholars, Enhancing Practice
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.